Biocon Biologics bags Rs 689 crore contract for Insugen from Malaysian Govt
The rh-Insulin formulations, Insugen-R, Insugen-N and lnsugen-30/70, are manufactured at Biocon Sdn. Bhd.'s Johor facility.
Bengaluru: Biocon Biologics Limited (BBL), a subsidiary of Biocon Ltd., has announced that its subsidiary Biocon Sdn. Bhd. in Malaysia has been awarded a three-year contract, valued at USD 90 million (MYR 375 million), for its recombinant human insulin brand Insugen, by the Ministry of Health (MoH), Malaysia.
Biocon Sdn. Bhd. a subsidiary of Biocon Biologics in Malaysia, will manufacture and supply its range of insulins to its partner Duopharma Marketing Sdn. Bhd. (DMktg), a subsidiary of Duopharma Biotech, a pharmaceutical & biotech company in Malaysia.
Biocon Biologics' Insugen formulations will be available to patients at all Ministry of Health hospitals, district health offices and health clinics.
Susheel Urnesh, Chief Commercial Officer, Emerging Markets, Biocon Biologics, said: "We are pleased to renew our commitment to provide affordable access to our recombinant human insulin for people with diabetes in Malaysia through this new government contract. This will enable us to serve over 400,000 people with diabetes using recombinant human insulin, helping the government in its journey towards equitable access to diabetes care."
Read also: Honour- Glasgow University research centre named after Biocon founders
The rh-Insulin formulations, Insugen-R, Insugen-N and lnsugen-30/70, are manufactured at Biocon Sdn. Bhd.'s Johor facility and have been approved by the National Pharmaceutical Regulatory Authority (NPRA), Malaysia.
Biocon Biologics has created a Center of Excellence (CoE) for insulins in Malaysia with end-to-end capabilities to manufacture a broad portfolio of regular, basal and rapid insulins. More recently, Biocon's biosimilar insulin Glargine made at Malaysia, has received a historic U.S. FDA approval as the `first interchangeable biosimilar'.
Read also: Biocon Biologics Inpremzia gets backing from EMA expert panel
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.